atopic dermatitis
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
September 18, 2025Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …
Dupixent improves symptoms in patients with skin of colour, study shows
June 11, 2025Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …
Sanofi shares phase 2b results for dermatitis treatment
March 12, 2024Research and Development Dermatology, Sanofi, amlitelimab, atopic dermatitis, clinical trial, dermatitis
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of amlitelimab for adult patients …
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
December 18, 2023Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis
May 3, 2023Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab
Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …
UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy
February 24, 2021Research and Development atopic dermatitis, eczema
Researchers at the University of California San Diego School of Medicine have identified a universal strain of bacteria derived from …
Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis
October 19, 2020Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis
Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis
June 22, 2020Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma
China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …
Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis
April 7, 2020Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib
Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …
Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis
April 3, 2020Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
October 14, 2019Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
August 7, 2019Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis
May 16, 2019Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …
